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The purpose of the study was to evaluate the influence of baseline haemoglobin level in predicting response to 5-fluorouracil (5FU)-
based first-line chemotherapy in advanced colorectal cancer patients. Data from 631 patients were collected from three different
institutions. Globally, overall response rate was 35.8% (226 out of 631). Factors influencing response rate were 5FU dose intensity
(high: 43.1%, low: 34.0%, P¼0.03); oxaliplatin (yes: 45.8%, no: 22.9%, Po0.0001), performance status (PS 0: 46.1%, 1: 28.8%, 2:
26.7%, Po0.0001), and haemoglobin levels (X12gdl
 1: 40.4%, o12gdl
 1: 29.2%, P¼0.004). In subgroup analysis significant
differences in response rate between anaemic and nonanaemic patients were recorded in those patients treated with infusional
chemotherapies (45.7 vs 25.5%, Po0.0001), with high 5FU dose intensity (50.3 vs 32.7%, P¼0.005), with PS¼0 (49.8 vs 37.9%,
P¼0.03), and with liver metastases (44.8 vs 33.8%, P¼0.002), whereas no difference was evident in those subjects treated with
bolus schedules or according to gender. Anaemia was a strong predictor for activity of first-line 5FU-based chemotherapy especially in
those groups that showed the best responses, for example high performance status, infusionally treated, higher 5FU dose and those
with liver secondaries. Patients with higher haemoglobin levels recorded a greater response rate and a longer time to progression and
survival than anaemic subjects. Prospective evaluation of role of correcting anaemia on response to therapy is justified by these
results.
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Malignant neoplasms of the large bowel are a leading health
problem in the western countries, representing the second most
frequent cause of cancer-related death (Parkin, 2001). The
backbone of treatment for colorectal cancer is 5-fluorouracil
(5FU), a fluorinated pyrimidine (Meyerhardt and Mayer, 2005).
The biochemical pharmacology of 5FU is well understood and has
been extensively reviewed (Pinedo and Peters, 1988; Diasio and
Harris, 1989). 5FU is a prodrug which requires anabolism for its
cytotoxic effects. Several anabolic pathways are recognized:
primarily conversion to FdUMP, which inhibits thymidylate
synthase (TS), the rate-limiting enzyme in pyrimidine nucleotide
synthesis; conversion to FUTP which can be incorporated to RNA;
conversion to FdUTP which can be incorporated into DNA.
Enzymes involved into these different pathways include thymidine
phosphorylase (TP) and thymidine kinase (TK). Furthermore, 5FU
is able to induce apoptosis in normal and tumoural intestinal cells
(Pritchard et al, 1988; Nita et al, 1998).
The overall response rate and the survival of metastatic
colorectal patients have been dramatically increased in the last
decade with the introduction of new active drugs, such as
oxaliplatin, irinotecan and more recently cetuximab and bevaci-
zumab, in combination with 5FU and capecitabine (Meyerhardt
and Mayer, 2005). Response rate increased from 15 to 25% of the
1990s up to 50–60% and overall survival passed from 12 months to
more than 20 months (Levi et al, 1999; Tournigand et al, 2004).
Interestingly, several meta-analyses analysing pooled data coming
from phase III trials on first-line treatment demonstrated that an
increase in tumour control translates into a gain in overall survival
(Buyse et al, 2000; Louvet et al, 2001). This finding seems to justify
further evaluation of new treatment strategies focused to increase
tumour response rate.
Anaemia is common in patients with cancer. Its prevalence
was reported to be 70–85% in patients with Hodgkin disease and
40–80% in patients with advanced colorectal cancer, according to
the cutoff considered (Knight et al, 2004). Haemoglobin level has
been reported to impact on chemotherapy outcomes in a number
of malignancies, particularly in breast (Bottini et al, 2003) and
other gynaecological cancers or in head and neck cancer, especially
when associated with radiotherapy (Koukourakis et al, 2000; Chua
et al, 2004; Winter et al, 2004). Most studies have reported low
pretreatment Hb levels to be a poor prognostic factor for tumour
control and/or patients survival. These findings are consistent with
experimental data. Several in vitro studies, in fact, demonstrated
that cancer cells that are sensitive to 5FU when normally
oxygenated may become resistant in hypoxic conditions (Teicher
et al, 1981; Tannock, 1987; Grau and Overgaard, 1992).
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sThe mechanism for this resistance has not been clarified yet. It
has been demonstrated that low haemoglobin levels resulted in
peripheral tissue hypoxia (Vaupel and Harrison, 2004), that may
produce cell death if severe or prolonged. Although hypoxia is
toxic to both cancer cells and normal cells, cancer cells undergo
genetic and adaptive changes that allow them to survive and even
proliferate in a hypoxic environment (Harris, 2002). Hypoxia
regulates different pathways including angiogenesis, growth factor
signalling, immortalisation, tissue invasion and metastasis, and
apoptosis. In particular, vascular endothelial growth factor
(VEGF)-A is a key factor (Harris, 2002). Vascular endothelial
growth factor is thought to be the most potent and specific
stimulator of angiogenesis and has been demonstrated to be
associated with recurrence, metastasis and prognosis in colorectal
cancer patients (Takahashi et al, 1995; Guba et al, 2004). Moreover,
hypoxia may attract macrophages, which deliver TNFa and
interleukin 1 in the tumour microenvironment. These inflamma-
tory cytokines upregulate the expression of TP (TP – also called
platelet-derived endothelial cell growth factor (PD-ECGF)), one of
the key enzymes for fluoropyrimidine metabolism, which acts also
as an antiapoptotic factor (Toi et al, 2005).
This body of clinical and preclinical evidences prompted us to
investigate whether haemoglobin levels at baseline can predict
response to first-line 5FU-based chemotherapy in patients with
advanced colorectal cancer.
MATERIALS AND METHODS
Patients
Patients were identified from the central databases of three
different institutions in which these patients were treated and
followed from June 1993 to April 2004. These institutions were: (1)
Universita ` degli Studi di Torino, Oncologia Medica, ASO San Luigi
di Orbassano; (2) Universita ` degli Studi di Torino, IRCC Candiolo;
(3) Universita ` degli Studi ‘G. Avogadro’, ASO Maggiore della
Carita `, Novara. Patients who met the following criteria were
selected for this study: (1) first diagnosis of metastatic colorectal
cancer; (2) first-line 5FU-based chemotherapy; (3) haemoglobin
determination within 1 week before first-line chemotherapy; (4) at
least one clinical response determination during therapy.
Response evaluation was performed according to each single
institution experience. It included at least clinical examination,
complete abdominal computed tomography or ultrasound scan,
and thoracic computed tomography scan or standard radiography.
Other radiological exams or biochemical determinations were
performed according to symptoms and metastatic sites.
Treatment response was classified according to the UICC
criteria (Miller et al, 1981). A complete response was defined as
the complete disappearance of all clinically detectable malignant
disease. A partial response was characterized as a decrease X50%
in the sum of the products of the two longest perpendicular
diameters of all measurable lesions. Progressive disease was
defined as an increase of at least 25% in the size of measurable
lesions and the development of new lesions. Only the best tumour
response was recorded.
Time to progression and overall survival were estimated from
treatment start till progression, death or date of the last follow-up
(30 April 2004). Patients not progressing, alive or lost to follow-up
at the time of data computation were censored at the time of the
last follow-up examination.
Data collection
In each institution, a team of three physicians filled in a
standardized electronic sheet including major demographic and
prognostic characteristics for every consecutive patient who met
the inclusion criteria. Data were abstracted from patient charts and
clinical records.
In order to assure good quality of the data, clinical response to
therapy was re-evaluated by three physicians (one from each
institution). As a whole, the radiological images of 290 patients
(46%) randomly chosen from the entire data set were reviewed,
with a concordance between recorded and re-evaluated responses
of 97%.
Electronic sheets were verified at the end of data collection to
eliminate data entry errors and were subsequently entered into a
computerized database, which represented the source file for this
study.
Statistical analyses
The area under the receiver operating characteristic curve (ROC)
was calculated as a measure of predictive discrimination of tumour
response by haemoglobin levels. An index of 0.5 indicates no
discrimination ability, whereas a value of 1 indicates perfect
discrimination.
Differences between groups of parametric variables were
validated by the t test for means. The difference between
proportions was evaluated by the w
2 test with Yates’ correction,
when necessary. Survival curves were plotted using the Kaplan–
Meier method and were statistically evaluated using the log-rank
test. Multivariate survival analysis according to the Cox model was
performed to eliminate confounding variables. Martingale and
Schoenfeld residuals were used to check the adequacy of the
linearity and the proportional hazard assumptions (Harrell et al,
1984).
These statistical computations were performed using the SPSS
for Windows and STATISTICA for Windows software.
RESULTS
Patient characteristics
A total of 631 patients met the inclusion criteria and were
considered in the study. Their characteristics are outlined on
Table 1. Median age was 61.2 years, 385 were male (61%) and most
of them were in good performance status (PS 0–1) at the time of
their first recurrence. More than a half of this study group
presented with synchronous metastases and 172 patients (27.3%)
received one line of adjuvant therapy. No patient received
oxaliplatin or irinotecan in the adjuvant setting. At study entry,
mean haemoglobin value was 12.5gdl
 1 (standard error of the
mean70.07gdl
 1). The relationship between haemoglobin levels
and various parameters are shown on Table 1. Differences were
evident when patients were stratified according to gender,
performance status, and whether or not they presented with liver
or lung metastases.
Chemotherapy regimens
Table 2 summarizes the types of chemotherapy administered to the
study population. Chronomodulated chemotherapy was adminis-
tered to 296 patients, whereas 205 of them received one of the
FOLFOX or FOLFIRI regimens (Tournigand et al, 2004). Infusional
5FU was administered to 380 patients, a combination of
bolusþinfusional 5FU to 211 patients and bolus 5FU to 40
patients. In the subsequent analyses, these two latter groups were
considered together to improve statistical power. Finally, 356
patients received 5FU combined with oxaliplatin and 50 with
irinotecan. The 5FU dose intensity was calculated for each patients
dividing the amount of the drug actually administered, expressed
as milligrams per square meter, by the time between chemotherapy
onset and the date of the last dispensed cycle, expressed as the
number of weeks between the two time points. Median 5FU dose
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sintensity was 1165mgsqmweek
 1 (range 96–4248). Differences in
median 5FU dose intensities were found when patients were
stratified according to the type of infusion (bolus group:
967mgsqmweek
 1; infusional group: 1341mgsqmweek
 1,
P¼0.02) and whether or not they received oxaliplatin (yes:
1225mgsqmweek
 1; no: 1037mgsqmweek
 1, P¼0.01). A lower
median 5FU dose intensity was administered to patients with PS 1
(1070mgsqmweek
 1) than those with PS 0 (1217mgsqmweek
 1)
or PS 2 (1212mgsqmweek
 1). This last difference, however, was
not statistically significant.
Response to chemotherapy
After chemotherapy, 226 patients obtained a tumour shrinkage
450% (overall response rate: 35.8%), 259 (41.1%) did not present
significant tumour changes within 3 months, and 146 progressed
(23.1%).
Univariate analyses of response rate and time to progression
according to various parameters are summarized on Table 3.
The World Health Organization (WHO) recognized as anaemic,
women with haemoglobin levels below 12.0gdl
 1 and men with
levels below 13.0gdl
 1 (WHO/UNICEF/UNU, 2001). Considering
these indications, the mean haemoglobin value of the study
population (12.5gdl
 1), and the response rate of patients stratified
by haemoglobin levels, the haemoglobin cutoff to discriminate
anaemic vs nonanaemic patients in this study was determined to
be 12.0gdl
 1.
Patients receiving a 5FU dose intensity higher than
1165mgsqmweek
 1 had a higher response rate (43.1 vs 34.0%;
X
2¼4.5, P¼0.03) and a longer time to progression (TTP) (11.6 vs
10.5 months, P¼0.07), even if this latter analysis did not reach a
fully statistical validation. Similar results were recorded in patients
receiving oxaliplatin (45.8 vs 22.9%, X
2¼35.3, Po0.0001; TTP 11.6
vs 9.8 months, P¼0.004), whereas they were not evident for those
treated with irinotecan (28.0 vs 36.5%, X
2¼1.1, P¼NS). Patients
with the best performance status responded better than those
in worse conditions. Response rates, in fact, were 46.1, 28.8, and
26.7%, respectively (Po0.0001). No difference in response rate was
found between patients treated with infusional 5FU regimens (141
out of 380, 37,1%) and those receiving bolus 5FU (85 out of 251,
33.9%; X
2 P¼0.4), whereas the corresponding times to progres-
sion were 11.8 vs 10.0 months (P¼0.004). Finally, male patients
presented the same chance to respond to therapy as female
subjects (36.1 vs 35.4%; X
2 P¼0.8).
Treatment response related to haemoglobin levels and
drug regimen
Figure 1 shows response rate by subgroup analyses according to
1gdl
 1 increments of haemoglobin levels, gender and type of
infusion. Overall, at each increment a higher response rate was
recorded, 43.6% being the highest at 14gdl
 1 cutoff. However, a
plateau between 12.0 and 14.0gdl
 1 was evident with response rate
ranging from 40.4 to 43.6%. No difference between genders was
recorded.
When analysing patients treated with bolus regimens, response
rates were similar regardless of gender and haemoglobin levels. A
different pattern, however, was evident in those patients treated
with infusional schedule. In fact, at each haemoglobin increment
Table 1 Patients’ characteristics
Total number of patients 631
Patients from centre #1 352
Patients from centre #2 53
Patients from centre #3 226
Male/female 385/246
Median age (range) 61.2 years (28.9–84.9)
Colon/rectum 464/167
PS 0/1/2/unknown 337/156/30/108
Stage at diagnosis
A2
B7 2
C 169
D 385
Unknown 3
Previous adjuvant therapy
Yes/no 172/459
Metastatic site at study entry
1 mts site 450 (71.3%)
41 mts site 181 (28.7%)
Liver 457/631 (72.4%)
Lung 165/631 (26.1%)
Abdomen 217/631 (34.4%)
Bone 7/631 (1.1%)
Mean Hb level (7s.e.m.) 12.5 (70.07)gdl
 1
Male 12.8 (71.8)
Female 12.0 (71.5) (Po0.0001)
Colon 12.5 (70.08)
Rectum 12.6 (70.14) (P¼NS)
PS 0 12.8 (70.09)
PS 1 12.2 (70.14)
PS 2 11.3 (70.33) (Po0.0001)
1 mts site 12.5 (70.08)
41 mts site 12.4 (70.14) (P¼NS)
Liver mts 12.4 (70.08)
No liver mts 12.7 (70.13) (P¼0.03)
Lung mts 12.4 (70.08)
No lung mts 12.9 (70.13) (Po0.01)
mts¼metastasis; NS¼not significant.
Table 2 First-line chemotherapy
Schedule 5FU administration No. of patients
Bolus FUFOL Bolus 22
LV5FU2 Bolus+infusional 31
5FU continuous infusion Infusional 49
FOLFOX2 Infusional 25
FOLFOX4 Bolus+infusional 61
FOLFOX6 Bolus+infusional 78
FOLFIRI Bolus+infusional 41
Chronomodulated FF Infusional 110
Chronomodulated FFL Infusional 186
Various bolus Bolus 18
Various infusional Infusional 10
LV5FU2: folinic acid 200mgsqmday
 1 2h infusion; 5FU 400mgsqmday
 1 bolus;
5FU 600mgsqmday
 1 22h infusion d1-2q14d FOLFOX2: oxaliplatin
100mgsqm
 1d1; folinic acid 300mgsqmday
 1 in 2h infusion; 5FU 1500–
1800mgsqmday
 1 in 22h infusion d1-2q14d FOLFOX4: oxaliplatin
85mgsqm
 1d1; folinic acid 200mgsqmday
 1 2h infusion; 5FU 400mgsqmday
 1
bolus; 5FU 600mgsqmday
 1 22h infusion d1-2q14d FOLFOX6: oxaliplatin
100mgsqmd1; folinic acid 200mgsqm
 1 2h infusion; 5FU 400mgsqm
 1 bolus;
5FU 2400–3000mgsqm
 1 46h infusion FOLFIRI: irinotecan 180mgsqm
 1d1;
folinic acid 200mgsqmday
 1 2h infusion; 5FU 400mgsqmday
 1 bolus; 5FU
600mgsqmday
 1 22h infusion d1-2q14d Chronomodulated FF: folinic acid
300mgsqmday
 1; 5FU 700–1000mgsqmday
 1 d1-4q14d Chronomodulated
FFL: oxaliplatin 25mgsqmday
 1; folinic acid 300mgsqmday
 1; 5FU 700–
1000mgsqmday
 1 d1-4q14d.
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scorresponded a higher response rate. This was particularly true
for male patients, in which the threshold of 14gdl
 1 was able to
discriminate the highest proportion of responding subjects,
whereas in female patients a plateau was evident at 12gdl
 1.
Overall response rates according to the o12g cutoff were 29.2%
(75 out of 257) in anaemic patients and 40.4% (151 out of 374) in
nonanaemic ones (X
2¼8.30; P¼0.004), whereas the times to
progression were 10.0 vs 11.7 months (Po0.001), and the median
overall survivals were 26.4 vs 20.2 (Po0.0001). When considering
all the patients obtaining a clinical response or a disease
stabilization after chemotherapy, the same figures were 67.3%
(173 out of 257) and 83.4% (312 out of 374), respectively
(X
2¼22.22; Po0.0001).
The area under the ROC curve calculated in the entire study
population to test the ability of haemoglobin values to discriminate
the patients destined to obtain a clinical response was 0.57 (95%CI
0.53–0.62, P¼0.001). Subgroup analyses revealed that the largest
area was found when computing the ROC curve in those patients
receiving infusional 5FU (0.64, 95%CI 0.58–0.69, Po0.001),
whereas this test did not describe a discrimination ability in those
patients treated with bolus 5FU. Taking into account these curves,
the best sensitivity/specificity ratio was found to be for haemoglo-
bin levels ranging between 11.0 and 13.0gdl
 1.
Progression and survival related to anaemia classified as
o12.0gdl
 1
Table 4 summarizes univariate response rate, time to progression,
and overall survival analyses for patients stratified according
to various parameters and haemoglobin levels. When patients
were stratified according to the modality of 5FU administration,
response rates were 25.5% (41 out of 161) in anaemic and 45.7%
(100 out of 219) in nonanaemic patients receiving an infusional
chemotherapy (X
2¼16.22; Po0.0001), whereas the same figures
were 35.4% (34 out of 96) and 32.9% (51 out of 155) in those
receiving bolus plus infusional 5FU (P¼NS), respectively. Patients
with haemoglobin values X12.0gdl
 1 presented a longer time to
progression either in the infusional subgroup (13.0 vs 10.4 mo,
P¼0.007) and in the bolus subgroup (10.1 vs 9.1 months,
P¼0.02), respectively, whereas a difference in overall survival
was evident only in those patients submitted to an infusional
regimen (27.5 vs 20.0 months, Po0.0001). When considering all
the patients obtaining a clinical response or a disease stabilization
after chemotherapy, the response rates were: infusional subgroup:
anaemic 68.3% (110 out of 161) vs nonanaemic 86.3% (189 out of
219) (X
2¼17.88, Po0.0001); bolus subgroup: anaemic 65.6% (63
out of 96) vs nonanaemic 79.4% (123 out of 155) (X
2¼5.82,
P¼0.015).
Among patients receiving more than 1165mgsqmweek
 1 of
5FU, those with normal haemoglobin levels had a higher response
Table 3 Univariate analyses of response to therapy, time to progression and overall survival
Response rate P TTP P OS P
Hb levelsX12gdl
 1 40.4% (151/374) 11.7 26.4
Hb levelso12gdl
 1 29.2% (75/257) 0.004 10.0 o0.001 20.2 o0.0001
5FU DI X1165mgsqmweek
 1 43.1% (110/255) 11.6 24.9
5FU DIo1165mgsqmweek
 1 34.0%(86/253) o0.0001 10.5 0.07 25.2 NS
Therapy with oxaliplatin 45.8% (163/356) 11.6 25.1
Therapy without oxaliplatin 22.9% (63/275) o0.0001 9.8 0.004 22.3 o0.001
Therapy with irinotecan 28% (14/50) 9.5 25.3
Therapy without irinotecan 36.5% (212/581) NS 10.9 NS 23.3 NS
Infusional regimen 37.1% (141/380) 11.8 23.9
Bolus+infusional regimen 33.5% (84/251) NS 10.0 0.004 23.3 NS
PS 0 46.1% (154/334) 11.9 29.0
PS 1 28.8% (45/156) 9.9 20.1
PS 2 26.7% (8/30) o0.001 7.6 o0.001 11.0 o0.0001
Liver mts 38.7% (177/457) 10.8 23.3
No liver mts 28.2% (49/174) 0.01 10.9 NS 24.7 NS
Lung mts 40.0% (66/165) 13.1 30.0
No lung mts 34.3% (160/466) NS 10.4 o0.001 22.2 o0.001
Male 36.1% (139/385) 11.0 24.3
Female 35.4% (87/246) NS 10.6 NS 23.2 NS
mts¼metastasis; NS¼not significant; OS¼overall survival (months); TTP¼time to progression (months).
0
10
20
30
40
50
60
9 1 01 11 21 31 4
Overall
Male
Female
g dl–1
R
e
s
p
o
n
s
e
 
r
a
t
e
 
(
%
)
Figure 1 Response rate by 1gdl
 1 increments of haemoglobin levels
overall and stratified by gender in the entire study population.
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sto chemotherapy (50.3 vs 32.7%, P¼0.005). This difference was
not found for patients who received a lower 5FU dose intensity
(34.9 vs 32.7%, respectively. P¼NS). Similar results were found
when considering the time to progression. Patients with normal
haemoglobin levels survived longer regardless the administered
dose of 5FU.
Differences in response rates were also found between anaemic
and nonanaemic patients when they were stratified according
whether or not they had received a chemotherapy containing
oxaliplatin. In fact, in those patients receiving oxaliplatin the
response rates were 39.4 vs 50.0% (P¼0.05), whereas the
corresponding figures in those patients not receiving oxaliplatin
were 18.1 vs 27.5% (P¼0.03), respectively.
When patients were stratified according to their performance
status, a clear difference between anaemic and nonanaemic patients
was evident in the subgroup with PS 0 (49.8 vs 37.9%, P¼0.03),
whereas there was a trend in that with PS 2 (44.0 vs 19.0%, P¼0.16)
and no difference in those patients with PS 1 (27.7 vs 27.4%).
Table 4 Univariate analyses of response to therapy, time to progression, and overall survival according to haemoglobin levels
RR P TTP P OS P
5FU DI X1165mgsqmweek
 1
Hb levels X12gdl
 1 50.3% (76/151) 12.8 28.1
Hb levelso12gdl
 1 32.7% (34/104) 0.005 10.1 0.002 22.0 o0.01
5FU DIo1165mgsqmweek
 1
Hb levels X12gdl
 1 34.9% (52/149) 10.8 27.8
Hb levelso12gdl
 1 32.7% (34/104) 0.7 10.2 0.33 21.6 o0.05
Infusional regimen
Hb levels X12gdl
 1 45.7% (100/219) 13.0 27.5
Hb levelso12gdl
 1 25.5% (41/161) o0.0001 10.4 0.007 20.0 o0.0001
Bolus+infusional regimen
Hb levels X12gdl
 1 32.9% (51/151) 10.1 24.3
Hb levelso12gdl
 1 35.4% (34/96) 0.8 9.1 0.02 20.3 NS
Therapy with oxaliplatin
Hb levels X12gdl
 1 50.0% (107/214) 12.8 28.4
Hb levelso12gdl
 1 39.4% (56/142) 0.05 10.5 0.002 22.1 o0.01
Therapy without oxaliplatin
Hb levels X12gdl
 1 27.5% (44/160) 10.6 24.6
Hb levelso12gdl
 1 18.1% (19/105) 0.03 8.6 0.09 18.3 o0.001
PS 0
Hb levels X12gdl
 1 49.8% (110/221) 13.5 30.1
Hb levelso12gdl
 1 37.9% (44/116) 0.03 10.8 0.003 25.3 o0.05
PS 1
Hb levels X12gdl
 1 27.7% (23/83) 9.6 22.3
Hb levelso12gdl
 1 27.4% (20/73) NS 10.0 NS 16.3 NS
PS 2
Hb levels X12gdl
 1 44.4% (4/9) 8.5 10.9
Hb levelso12gdl
 1 19.0% (4/21) 0.16 7.0 NS 10.9 NS
Liver mts
Hb levels X12gdl
 1 44.8% (116/259) 12.0 25.9
Hb levelso12gdl
 1 30.8% (61/198) 0.002 9.9 o0.001 20.1 o0.001
No liver mts
Hb levels X12gdl
 1 30.4% (35/115) 11.2 26.6
Hb levelso12gdl
 1 23.7% (14/59) NS 10.4 NS 19.0 o0.05
Lung mts
Hb levels X12gdl
 1 44.1% (49/111) 14.2 35.1
Hb levelso12gdl
 1 31.5% (17/54) 0.12 11.6 0.04 25.1 o0.01
No lung mts
Hb levels Xgdl
 1 38.8% (102/263) 11.2 23.7
Hb levelso12gdl
 1 28.6% (58/203) 0.02 9.8 0.01 18.3 o0.01
Male
Hb levels X12gdl
 1 41.2% (106/257) 11.8 27.5
Hb levelso12gdl
 1 25.8% (33/128) 0.03 9.4 o0.001 18.8 o0.0001
Female
Hb levels X12gdl
 1 38.5% (45/117) 11.5 24.6
Hb levelso12gdl
 1 32.6% (42/129) NS 10.2 0.05 21.6 0.05
mts¼metastasis; NS¼not significant.
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sMultivariate analysis of haemoglobin as a continuous
variable related to response and survival
Multivariate logistic regression analysis confirmed haemoglobin
levels at baseline (as a continuous variable), oxaliplatin, liver
metastasis and PS as independent predictive factors for response
to first-line chemotherapy. Gender, age, stage at diagnosis, tumour
grading, disease free interval, 5FU dose intensity, metastasis in
lung or abdomen and number of involved sites did not enter the
model (Table 5a).
Similar results were evident when performing the multivariate
survival analysis according to the Cox model, with the only
expected exception of the presence of lung metastasis as
independent positive factor for prolonged survival (Table 5b).
DISCUSSION
Anaemia was a strong predictor for activity of first-line 5FU-based
chemotherapy in 631 advanced colorectal cancer patients. Both
the ROC analysis and the multivariate model demonstrated that
patients with higher haemoglobin levels had a greater chance of
response to therapy. Although this study is retrospective and
involves several institutions, the observations provide a necessary
basis to consider prospective studies to evaluate the role of
transfusion or erythropoietin in this context.
The activity of first-line chemotherapy in our study population
is similar to that reported in the literature (Meyerhardt and Mayer,
2005). Response rates were 22.9% in those patients receiving 5FU
with or without folinic acid, and 45.8% in those receiving also
oxaliplatin. In our study, a high proportion of patients (56.4%) had
an oxaliplatin-containing regimen, whereas few patients received
irinotecan (7.9%). This was because institution #1 participated in
several clinical phase II–III studies aiming to validate oxaliplatin-
based chronochemotherapy in the early 1990s (Levi et al, 1994,
1997), and that institution #3 started to administer oxaliplatin
before it was registered in the Italian market. This hampered any
conclusion on the possible effect of anaemia on the activity of
irinotecan.
It is well known that haemoglobin distributions vary with age,
gender and with altitude and smoking. This observation was
confirmed in our patients (Table 1). The WHO defined haemoglo-
bin levels below which anaemia is present in an adult population as
12.0gdl
 1 in women and 13gdl
 1 in men (WHO/UNICEF/UNU,
2001). In the literature, many authors reported as ‘mild’, anaemic
cancer patients with haemoglobin levels below 11gdl
 1, while
those with levels below 9gdl
 1 were defined as with ‘severe’
anaemia (Knight et al, 2004). According to this evidence and to the
computed ROC curve of our series that indicated the best cutoff of
haemoglobin being between 11.0 and 13.0gdl
 1, we decided to
classify as anaemic all the patients with values below 12.0gdl
 1.
According to the response rates recorded dividing patients by
1gdl
 1 increment (Figure 1), while this cutoff might be ideal for
women, it may be questionable for male patients, in which the
highest chance to respond to therapy was recorded in those with
haemoglobin levels above 14gdl
 1. For treatment purposes (e.g.
blood transfusions or erythropoietin therapy), however, 12gdl
 1 is
a reasonable target, 14gdl
 1 being at risk of higher side effect
incidence. Finally, no difference according to gender was evident
in the multivariate analyses of response and survival (Table 5)
demonstrating that gender did not affect response rate.
With this relatively high cutoff we tried to reduce the impact of
potential biases of this study linked to the observation, confirmed
in our series (Table 3), that subjects with low haemoglobin levels
have low quality of life scores when compared to subjects with
greater levels (Holzner et al, 2002), and this condition might not
permit aggressive oncological approaches. Interestingly, when
considering only patients with PS 0, anaemic patients had a lower
response rate than those with normal haemoglobin levels,
suggesting an independent impact of these two factors. Multi-
variate regression analysis, in fact, together with oxaliplatin
administration and the presence of liver metastases, confirmed
performance status and haemoglobin levels as independent
variables in determining response (Table 5). It has to be
underlined that in this analysis haemoglobin levels were con-
sidered as continuous variable. Thus, the results obtained
suggested that the higher haemoglobin level, the higher chances
to respond to chemotherapy patients presented.
How anaemia may impact on treatment outcome is not clear.
One way that cells respond to reduced oxygen levels is through
hypoxia-inducible factor-1 (HIF-1) (Harris, 2002). Hypoxia-
inducible factor-1 is a key transcription factor that regulates many
pathways including angiogenesis, growth-factor signalling, tissue
invasion and metastasis. Hypoxia-inducible factor-1 accumulation
induces the gene expression of VEGF, of VEGF receptor 1 and can
also lead to reduced expression of antiangiogenic proteins such
as thrombospondin-1 and –2 (Harris, 2002). Vascular endothelial
growth factor acts as a powerful mitogen to endothelial cells,
induces vascular permeability, increases microvessel density,
increases the incidence of metastasis, and decreases the apoptotic
index upregulating endothelial antiapoptotic proteins (Perrone
et al, 2004). Violette et al (2002) demonstrated that the resistance
of colon cancer cells to long-term 5FU exposure in vitro is
correlated to the relative level of bcl-2 in addition to the status of
other proteins involved into the apoptotic pathways.
A second mechanism probably involved in drug resistance is
through the upregulation of the gene expression of PD-ECGF also
known as TP (Harris, 2002) mediated by several cytokines such as
tumour necrosis factor-a, interleukin 1, and interferon-d typically
associated with macrophage infiltration which is often related to
hypoxia (Lewis and Murdoch, 2005; Toi et al, 2005). Thymidine
phosphorylase has been repeatedly reported to be associated in
vivo with nonresponse to 5FU (Metzger et al, 1998; Ackland and
Peters, 1999; Salonga et al, 2000; van Triest et al, 2000). This could
be explained in several ways: similarly to VEGF and other growth
factor induced by hypoxia, TP might act as an angiogenesis factor
with reduction of the apoptotic propensity in tumour cells (Lu and
Tanigawa, 1997). Alternatively, TP might increase the incorpora-
tion of thymine into DNA independently from the activity of TS,
the target enzyme of 5FU, representing a possible rescue pathway
against 5FU cytotoxicity. This mechanism, however, has been
repeatedly questioned and new in vivo studies focusing on this
possible mechanism are required (Patterson et al, 1998; Ackland
and Peters, 1999; de Bruin et al, 2003). Finally, higher TP levels
Table 5 Multivariate analyses
b
Standard
error of b P-level
(a) Logistic multivariate regression analysis for clinical response
Liver metastasis 0.097 0.043 0.02
Haemoglobin value 0.096 0.044 0.03
Performance status  0.130 0.044 0.003
Chemotherapy with oxaliplatin 0.144 0.043 0.0001
(b) Multivariate survival analysis according to the Cox model
Lung metastasis  0.322 0.118 0.006
Haemoglobin value  0.127 0.029 o0.0001
Performance status 0.436 0.088 o0.0001
Chemotherapy with oxaliplatin  0.256 0.100 0.01
Lung metastasis: 1 yes; 0 no; Liver metastasis: 1 yes; 0 no Haemoglobin values as a
continuous variable. Performance status: 0, 1, 2. Chemotherapy with oxaliplatin: 1 yes;
0 no. Gender, age, stage at diagnosis, tumour grading, disease-free interval, 5FU dose
intensity, metastasis in liver or abdomen and number of involved sites did not enter
the model.
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smight divert 5FU to DNA rather than RNA pathway, the latter
being possibly linked to an oxygen-independent cell death
mechanism. It has been shown, in fact, that the level of 5FU
incorporated into RNA is significantly higher in patients treated
with bolus intravenous injection (bolus group) than in those who
received continuous drug infusion (continuous group), whereas
the TS inhibition was similar in both groups. Thus, cytotoxicity of
5FU was explained by RNA and DNA damage in the bolus group
and only by DNA damage in the continuous group (Kubota et al,
2002; Noordhuis et al, 2004). The reactions catalysed by TP (i.e. the
formation of 5-fluoro-deoxyuridine from 5FU and of thymine from
thymidine) are involved in the 5FU pathways that result in TS
inhibition and consequently in the DNA damage, whereas they
have little or no effects on the RNA formation. Moreover, the
decrease in proliferation index induced by hypoxia, may explain
the survival of cancer cells in which the DNA has been damaged by
5FU, whereas a defect in the expression of either mRNA or rRNA
due to 5FU might represent a mechanism of cell death less
modified by hypoxia. This is consistent with our data which
interestingly showed that the most striking difference in response
rate between anaemic and nonanaemic patients was evident only in
those subjects treated with infusional chemotherapy.
In our study only 40 patients (6.3%) received a 5FU bolus
regimen. This sample was too small for any statistical inference
and these subjects were pooled together with those receiving a
combination of bolus plus infusional 5FU. Considering this last
subgroup, while no disparity was evident in response rate, a
significative difference between anaemic and nonanaemic patients
was found when we considered the fraction of those patients
obtaining either clinical response or stabilisation of the disease. It
would be of great interest to perform similar analyses in those
patients submitted to a pure, active 5FU bolus schedule like the IFL
or the AIO regimens to determine whether this difference in
response is due to biochemical reasons or simply to the fact that
the Mayo or the Machover schedules are therapies with low
activity.
Finally, it should be noted the effect of anaemia was detected in
the groups with optimal criteria for response, for example, high
performance status and high drug intensity, but with less active
regimens or iller patients no effect was seen. It is likely that with an
already low response rate effects of further detrimental factors will
be harder to detect and less influential if outcome is already poor.
This emphasizes the importance of delivering optimal therapy to
those most likely to benefit. In view of recent controversies on
erythropoietin (Bohlius et al, 2005), it is not clear whether
haemoglobin should be maintained by transfusion or erythropoie-
tin therapy, our results suggest this is an important topic for a
randomised trial.
In conclusion, our data suggest that it would be of great
importance to maintain adequate haemoglobin levels to obtain the
best activity of first-line chemotherapy regimens, especially those
that foresee the infusional administration of 5FU.
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